State Street’s NervGen Pharma NGEN Stock Holding History

State Street’s Portfolio NGEN Stock Details NGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$117K	Buy	+61,300	New	+$117K	﹤0.01%	4050

Other funds holding NGEN

Valley Forge Investment Consultants Audubon, Pennsylvania $405M AUM 13.69% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

PFG Investments Woodbury, New York $2.64B AUM 26.11% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $67.2B AUM 18.61% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

United Capital Financial Advisors Irving, Texas $18.4B AUM 17.63% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

State Street's NGEN Position: Q3 2026 in Review

State Street opened a new position in NervGen Pharma (NGEN) in Q3 2026: 61,300 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #4050 among its holdings.

39 funds tracked by Wall St. Rank hold NGEN as of Q3 2026.

State Street held 61,300 shares of NervGen Pharma worth $117K as of Q3 2026.
NervGen Pharma was a new State Street position in Q3 2026.
NervGen Pharma made up ﹤0.01% of State Street's portfolio in Q3 2026, its #4050 holding.
39 funds tracked by Wall St. Rank held NervGen Pharma as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.